Literature DB >> 19940834

HIV infection among injection-drug users - 34 states, 2004-2007.

.   

Abstract

Injection-drug users (IDUs) acquire human immunodeficiency virus (HIV) infection by sharing drug equipment with HIV-infected persons and by engaging in risky sexual behavior. In 2007, injection-drug use was the third most frequently reported risk factor for HIV infection in the United States, after male-to-male sexual contact and high-risk heterosexual contact. To characterize HIV-infected IDUs aged >or=13 years in the United States, CDC analyzed data from the national notifiable disease reporting system for 2004-2007 from the 34 states that had conducted confidential, name-based HIV surveillance since at least 2003. The results of that analysis indicated that, during 2004-2007, 62.2% of IDUs with a new diagnosis of HIV infection were males, 57.5% were blacks or African Americans, and 74.8% lived in urban areas at the time of their HIV diagnosis. In addition, during 2004-2006, approximately 40% of HIV-infected IDUs received late HIV diagnoses (i.e., diagnosis of acquired immunodeficiency syndrome [AIDS] <12 months after the date of HIV diagnosis). To reduce the prevalence of HIV infection and late HIV diagnosis among IDUs, HIV prevention programs serving IDUs should have comprehensive approaches that incorporate access to HIV testing as part of community-based outreach, drug abuse treatment, and syringe exchange programs.

Entities:  

Mesh:

Year:  2009        PMID: 19940834

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  24 in total

1.  Harmful microinjecting practices among a cohort of injection drug users in vancouver Canada.

Authors:  Beth Rachlis; Elisa Lloyd-Smith; Will Small; Diane Tobin; Dave Stone; Kathy Li; Evan Wood; Thomas Kerr
Journal:  Subst Use Misuse       Date:  2010-07       Impact factor: 2.164

Review 2.  Drug treatment as HIV prevention: a research update.

Authors:  David S Metzger; George E Woody; Charles P O'Brien
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12       Impact factor: 3.731

Review 3.  Linkage to care for HIV-infected heterosexual men in the United States.

Authors:  Nickolas D Zaller; Jeannia J Fu; Amy Nunn; Curt G Beckwith
Journal:  Clin Infect Dis       Date:  2011-01-15       Impact factor: 9.079

Review 4.  Epigenetics of µ-opioid receptors: intersection with HIV-1 infection of the central nervous system.

Authors:  Patrick M Regan; Rajnish S Dave; Prasun K Datta; Kamel Khalili
Journal:  J Cell Physiol       Date:  2012-07       Impact factor: 6.384

5.  Improvement in the health of HIV-infected persons in care: reducing disparities.

Authors:  Richard D Moore; Jeanne C Keruly; John G Bartlett
Journal:  Clin Infect Dis       Date:  2012-09-26       Impact factor: 9.079

6.  HIV-gp120 and physical dependence to buprenorphine.

Authors:  J Palma; M E Abood; K Benamar
Journal:  Drug Alcohol Depend       Date:  2015-02-26       Impact factor: 4.492

Review 7.  The New Kid on the Block--Incorporating Buprenorphine into a Medical Toxicology Practice.

Authors:  Timothy J Wiegand
Journal:  J Med Toxicol       Date:  2016-03

8.  Epidemiology of HIV among injecting and non-injecting drug users: current trends and implications for interventions.

Authors:  Steffanie A Strathdee; Jamila K Stockman
Journal:  Curr HIV/AIDS Rep       Date:  2010-05       Impact factor: 5.071

9.  Longitudinal changes in engagement in care and viral suppression for HIV-infected injection drug users.

Authors:  Ryan P Westergaard; Timothy Hess; Jacquie Astemborski; Shruti H Mehta; Gregory D Kirk
Journal:  AIDS       Date:  2013-10-23       Impact factor: 4.177

10.  Cost-effectiveness analysis of Recovery Management Checkups (RMC) for adults with chronic substance use disorders: evidence from a 4-year randomized trial.

Authors:  Kathryn E McCollister; Michael T French; Derek M Freitas; Michael L Dennis; Christy K Scott; Rodney R Funk
Journal:  Addiction       Date:  2013-10-09       Impact factor: 6.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.